Introduction
============

Pulmonary arterial hypertension (PAH) is a rare, progressive disease characterized by remodeling of the pulmonary vasculature leading to a progressive increase in pulmonary vascular resistance (PVR) and mean pulmonary arterial pressure.[@b1-cmc-7-2013-029] PAH is commonly associated with congenital heart disease (CHD) and can develop earlier or later in life depending on size and location of the underlying defect. Recent data from a US registry reported that PAH-CHD was the second most prevalent etiology within the associated PAH patient subgroup.[@b2-cmc-7-2013-029]

Patients with PAH-CHD are at risk of developing right-to-left cardiac shunting, that is, Eisenmenger syndrome (ES). ES patients must make certain lifestyle adjustments due to limited functional capacity. Exercise capacity and quality of life (QOL) are also diminished.[@b3-cmc-7-2013-029] Moreover, there are a number of associated life-threatening complications and life expectancy is poorer than in the general population.[@b4-cmc-7-2013-029]

Congenital heart defects are highly prevalent (40%--58%) in patients with Down syndrome (DS).[@b5-cmc-7-2013-029],[@b6-cmc-7-2013-029] Patients with DS and CHD are considered to be at higher risk for PAH[@b3-cmc-7-2013-029],[@b7-cmc-7-2013-029] and ES[@b3-cmc-7-2013-029] (Defined within the Pulmonary Hypertension World Health Organisation (WHO) clinical classification system (Dana Point 2008) as Group 1), probably due to different pathogenetic factors.[@b7-cmc-7-2013-029]--[@b12-cmc-7-2013-029]

According to European Society of Cardiology/European Respiratory Society (ESC/ERS) guidelines,[@b13-cmc-7-2013-029] ES represents the most advanced form of PAH-CHD and is characterized by a reversed pulmonary-to-systemic (right-to-left) shunt and central cyanosis. Several studies in adult patients with ES have reported a persistent beneficial effect of bosentan (an oral dual endothelin receptor antagonist) on exercise capacity and clinical status without any worsening of pulmonary-to-systemic shunt.[@b14-cmc-7-2013-029]--[@b17-cmc-7-2013-029] In an open-label study, 24 patients with DS-ES were treated with bosentan with a median follow-up period of 11.5 months.[@b18-cmc-7-2013-029] The authors concluded that medical treatment was well tolerated in DS-ES patients and that results in patients with DS did not deviate from those observed in ES alone.[@b18-cmc-7-2013-029] The same authors in a retrospective study reported on the effect of almost 2 years of bosentan treatment on exercise capacity and QOL in 58 adult patients with PAH-CHD with and without DS.[@b19-cmc-7-2013-029] The results showed that in DS, patient's 6-minute walk distance (6MWD) and QOL were stable during treatment. The aim of our retrospective study was to evaluate the effect of long-term treatment with bosentan in adult patients with DS-ES.

Methods
=======

This was a retrospective analysis of data collected prospectively from all patients with DS-ES treated and undergoing active follow-up at our center (Department of Internal and Vascular Medicine IRCCS, Policlinico, San Donato Milano, Italy) between September 2008 and December 2010. Permission to prospectively collect patient data was obtained from the parents or the patients' legal guardians. The authors of this manuscript have certified that they comply with the ethical standards of the responsible committee and with the Helsinki Declaration.[@b20-cmc-7-2013-029]

Eisenmenger syndrome was diagnosed prior to, or following, referral to our center, based on clinical and echocardiographic features and confirmed by right heart catheterization. It was required that patients included in this analysis had stable PAH for at least 1 month prior to the study, that is, had no sign of acute heart failure. Patients with concomitant causes of pulmonary hypertension, such as lung, liver, or connective tissue disease, were excluded from this analysis.

All patients received bosentan (Tracleer^®^, Actelion Pharmaceuticals Ltd., Allschwil, Switzerland) treatment, which was started at an oral dose of 62.5 mg twice a day and increased to the target dose of 125 mg twice a day after 4 weeks. Patients started on bosentan therapy following a diagnosis of ES and subsequent assessment by our center confirming that they were suitable candidates for this treatment, that is, they were in New York Heart Association (NYHA) functional class (FC) above II. Bosentan is the first-line treatment of choice for ES-DS patients at our center.

Submaximal exercise capacity was assessed using 6MWD according to the guidelines of the American Thoracic Society (ATS), and transcutaneous arterial oxygen saturation was measured by continuous pulse oximetry monitoring (ATS guidelines) before and after 6MWD testing.[@b21-cmc-7-2013-029] Functional capacity was assessed using the NYHA FC system, by the same representative parent or guardian on behalf of the patient at each assessment point. Right ventricular function was measured using tricuspid annular plane systolic excursion (TAPSE), and systolic pulmonary arterial pressure (PAPs) was estimated using peak velocity of the tricuspid regurgitation jet with continuous wave Doppler. These parameters were evaluated at baseline and every 6 months during bosentan therapy. Parameters such as mortality, hospitalization, additional PAH therapy, and cardiac surgery that collectively signify clinical worsening were also recorded and assessed. Laboratory tests (including hemoglobin, liver function, and uric acid) were evaluated every 2 weeks during the first 2 months and every 2 months thereafter. All patients were subjected to a baseline electrocardiogram and a chest X-ray.

Statistical analysis
--------------------

Statistical analysis was performed applying the Shapiro-Wilk W test. Measured variables (6MWD, oxygen saturation, NYHA FC, PAPs, and TAPSE) were statistically analyzed at baseline, 12 months, and at the end of the study period (24 months). Clinical and instrumental parameter changes from baseline were controlled and a *P* value \< 0.05 was considered as a level of statistical significance.

Results
=======

Seven adult patients with DS-ES, five male (72%) and two female (28%) with a mean age 31.7 years (range 20--50 years), were included in this analysis. The majority of patients (5/7) had ventricular septal defect (VSD) ([Table 1](#t1-cmc-7-2013-029){ref-type="table"}). Patients had not received corrective cardiac surgery. As these patients were referred to our center in adulthood, the reasons why they were not operated on in infancy were unknown. No patient received anticoagulant therapy or sildenafil therapy; concomitant medications for each patient are provided on [Table 2](#t2-cmc-7-2013-029){ref-type="table"}.

In the first 6 and 12 months of bosentan therapy, patients showed an increase in 6MWD compared with baseline values ([Figs. 1](#f1-cmc-7-2013-029){ref-type="fig"} and [2](#f2-cmc-7-2013-029){ref-type="fig"}). Median 6MWD increased from 252 m at baseline to 320 m at 12 months (*P* = 0.10) and after 24 months 6MWD was maintained compared with the 12 month value (median 310 m, *P* = 0.20). Mean ± standard deviation 6MWD was 261 ± 64 m at baseline, 306 ± 62 m at 12 months, and 298 ± 60 m at 24 months. There was no significant variation of oxygen saturation before and after 6MWD testing over the 2-year course of follow-up ([Fig. 3](#f3-cmc-7-2013-029){ref-type="fig"}). Overall, patients experienced a statistically significant improvement in NYHA FC ([Fig. 4](#f4-cmc-7-2013-029){ref-type="fig"}; *P* = 0.01). After 24 months of therapy, two patients improved from their baseline NYHA FC from IV to III, and four patients, from NYHA FC III to II. One 50 year-old male patient with perimembranous VSD and aortic valve insufficiency who initially remained in NYHC FC III worsened into NYHA FC IV after 24 months' treatment. There was no significant change in Doppler echocardiography data (TAPSE, PAPs, and absence of pericardial effusion) observed. No patients required hospitalization for PAH or additional PAH therapy because of progression of disease in the 2-year observation period, and no patients required cardiac surgery.

Bosentan treatment was generally well tolerated and no serious adverse drug reactions were recorded. All seven patients with DS-ES tolerated induction of oral bosentan therapy and there was no indication of decreased arterial oxygen saturation over the treatment period studied. No liver function abnormalities (\>3 × upper limit of normal) were noted and uric acid, hemoglobin, white blood cells, and platelet count were unchanged during bosentan treatment.

Discussion
==========

Overall, the DS-ES patients treated with bosentan in our study showed initial improvement in exercise capacity, as shown by the median and mean increases from baseline at 12 months, which was subsequently maintained up to 2 years. Although the changes from baseline in 6MWD at 12 and 24 months were not statistically significant, they are clinically meaningful. Given the progressive nature of ES, the fact that three patients showed an increase in 6MWD and the other four remained stable over the course of 2 years (even in one patient who was overweight) is encouraging (see [Fig. 2](#f2-cmc-7-2013-029){ref-type="fig"} for individual patient data). Furthermore, NYHA FC improved in six patients over the course of the study providing strong supportive evidence that most of these patients derived a benefit from bosentan treatment over the long term. In addition, patients in our study did not exhibit any of the clinical parameters associated with clinical worsening, that is, death, hospitalization due to PAH, or a requirement for additional PAH therapy or cardiac surgery, although one patient did worsen to NYHA FC IV after 24 months' treatment. We have shown long-term benefits in exercise capacity (6MWD) and NYHA FC in DS-ES patients treated with bosentan combined with a favorable safety profile in accordance with previously published literature.[@b15-cmc-7-2013-029],[@b18-cmc-7-2013-029],[@b19-cmc-7-2013-029],[@b22-cmc-7-2013-029]--[@b25-cmc-7-2013-029]

In our center, bosentan is selected as the first-line treatment for patients with DS-ES, based on the recommendations given in guidelines for the treatment of ES patients[@b13-cmc-7-2013-029] and the fact that sildenafil may have sexual side effects in men. Sildenafil may be initiated in combination with bosentan if a patient's 6MWD decreases by at least 10% compared with the previous value and there are other indicators consistent with deterioration and no ethical impediments. None of the patients received targeted PAH combination therapy during the study period.

The BREATHE-5 study was the first to demonstrate improvements in hemodynamics and exercise capacity after treatment with bosentan in patients with ES.[@b16-cmc-7-2013-029] The study's open-label extension confirms the early results over a longer treatment period of 40 weeks.[@b26-cmc-7-2013-029] A subgroup analysis of the BREATHE-5 patient population showed that the location of septal defect was a key determinant of treatment response.[@b27-cmc-7-2013-029]

In our study, during the follow-up period, DS-ES patients showed and maintained an increased 6MWD. Additionally, the patients' FC improved significantly during follow-up. Our data add to and support the findings reported in the literature on the effects of targeted PAH therapies in this patient population. Duffels et al reported an improvement or stability in QOL and 6MWD with long-term bosentan administration in patients with DS-ES.[@b18-cmc-7-2013-029],[@b19-cmc-7-2013-029] A further study also showed an improved 6MWD in three DS-ES patients during long-term treatment with bosentan.[@b28-cmc-7-2013-029] More recently, several articles have been published regarding the efficacy of bosentan therapy in this subset of patients. Two long-term studies demonstrated a prolonged beneficial effect of bosentan treatment on exercise capacity and main hemodynamic parameters.[@b22-cmc-7-2013-029],[@b23-cmc-7-2013-029] Monfredi et al[@b24-cmc-7-2013-029] using the same method of follow-up, confirmed the efficacy and safety data of bosentan.

Prior to the era of targeted PAH therapies, survival of patients with ES was calculated to be 97% at 1 year, 89% at 2 years, and 77% at 3 years, which were higher than the comparable rates for patients with idiopathic PAH (77%, 69%, and 35%, at 1, 2 and 3 years, respectively).[@b29-cmc-7-2013-029] While these data may suggest that ES patients have a more stable disease course than idiopathic PAH patients, this does not mean that ES patients would not derive benefits from PAH therapy in terms of survival. Until recently, there has been little evidence regarding the survival benefits of targeted PAH therapy in patients with ES. A single center study has recently provided the first evidence that targeted PAH therapies can significantly reduce the risk of death in ES patients.[@b27-cmc-7-2013-029]

Study strengths and limitations
-------------------------------

The present study adds valuable evidence to the limited information reported in the literature regarding patients with DS-ES treated with the dual endothelin receptor antagonist, bosentan. This study demonstrated a significant and stable long-term clinical improvement with a favorable safety profile in accordance with previous reports. However, this study is subject to a number of limitations. These include the lack of a control group and the small sample size, but this is not surprising considering the low prevalence of this dual syndrome. Nevertheless, our observations are in line with other recent studies.[@b18-cmc-7-2013-029],[@b19-cmc-7-2013-029],[@b22-cmc-7-2013-029]--[@b25-cmc-7-2013-029]

Conclusions
===========

In conclusion, in our experience and in accordance with latest literature, bosentan has been shown to be well tolerated and clinically effective in patients with DS-ES, and the clinical benefit is maintained over a long-term treatment period.
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###### 

Individual patient characteristics at baseline.

  **Patient**   **Gender**   **Age, years**   **Weight, kg**   **Body mass index, kg/m^2^**   **CHD**   **NYHA FC**   **6MWD, m**
  ------------- ------------ ---------------- ---------------- ------------------------------ --------- ------------- -------------
  1             Male         34               47               17                             AVC       IV            220
  2             Male         24               108              42                             VSD       III           310
  3             Female       20               55               20                             VSD       IV            180
  4             Male         21               64               22                             VSD       III           360
  5             Male         41               74               27                             VSD       III           200
  6             Male         50               65               24                             VSD       III           300
  7             Female       32               60               24                             AVC       III           200

**Abbreviations:** AVC, atrioventricular canal; VSD, ventricular septal defect.

###### 

Individual baseline medications.

  **Patient**   **Medication**
  ------------- ------------------------------------------
  1             Digoxin + diuretics + allopurinol + iron
  2             Diuretics + aspirin + iron
  3             Iron
  4             Diuretics + allopurinol
  5             Diuretics + iron
  6             Digoxin + diuretics + allopurinol
  7             Iron
